A tool to predict progression of non-alcoholic ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients
Author(s) :
Bauvin, Pierre [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Delacote, Claire [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lassailly, Guillaume [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Ntandja Wandji, Line [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Gnemmi, Viviane [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Dautrecque, Flavien [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Louvet, Alexandre [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Caiazzo, Robert [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Raverdy, Violeta [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Leteurtre, Emmanuelle [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Pattou, Francois [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Deuffic-Burban, Sylvie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Mathurin, Philippe [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Delacote, Claire [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lassailly, Guillaume [Auteur]

Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Ntandja Wandji, Line [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Gnemmi, Viviane [Auteur]

Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Dautrecque, Flavien [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Louvet, Alexandre [Auteur]

Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Caiazzo, Robert [Auteur]

Recherche translationnelle sur le diabète (RTD) - U1190
Raverdy, Violeta [Auteur]

Recherche translationnelle sur le diabète (RTD) - U1190
Leteurtre, Emmanuelle [Auteur]

Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Pattou, Francois [Auteur]

Recherche translationnelle sur le diabète (RTD) - U1190
Deuffic-Burban, Sylvie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Mathurin, Philippe [Auteur]

Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Journal title :
Liver International
Abbreviated title :
Liver Int.
Publication date :
2020-09-03
ISSN :
1478-3231
Keyword(s) :
fibrosis
NASH
risk factors
disease progression
Markov model
NASH
risk factors
disease progression
Markov model
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Severely obese patients are a growing population at risk of non-alcoholic fatty liver disease (NAFLD). Considering the increasing burden, a predictive tool of NAFLD progression would be of interest. Our objective was to ...
Show more >Severely obese patients are a growing population at risk of non-alcoholic fatty liver disease (NAFLD). Considering the increasing burden, a predictive tool of NAFLD progression would be of interest. Our objective was to provide a tool allowing general practitioners to identify and refer the patients most at risk, and specialists to estimate disease progression and adapt the therapeutic strategy. This predictive tool is based on a Markov model simulating steatosis, fibrosis and non-alcoholic steatohepatitis (NASH) evolution. This model was developped from data of 1801 severely obese, bariatric surgery candidates, with histological assessment, integrating duration of exposure to risk factors. It is then able to predict current disease severity in the absence of assessment, and future cirrhosis risk based on current stage. The model quantifies the impact of sex, body-mass index at 20, diabetes, age of overweight onset, on progression. For example, for 40-year-old severely obese patients seen by the general practitioners: (a) non-diabetic woman overweight at 20, and (b) diabetic man overweight at 10, without disease assessment, the model predicts their current risk to have NASH or F3-F4: for (a) 5.7% and 0.6%, for (b) 16.1% and 10.0% respectively. If those patients have been diagnosed F2 by the specialist, the model predicts the 5-year cirrhosis risk: 1.8% in the absence of NASH and 6.0% in its presence for (a), 10.3% and 26.7% respectively, for (b). This model provides a decision-making tool to predict the risk of liver disease that could help manage severely obese patients.Show less >
Show more >Severely obese patients are a growing population at risk of non-alcoholic fatty liver disease (NAFLD). Considering the increasing burden, a predictive tool of NAFLD progression would be of interest. Our objective was to provide a tool allowing general practitioners to identify and refer the patients most at risk, and specialists to estimate disease progression and adapt the therapeutic strategy. This predictive tool is based on a Markov model simulating steatosis, fibrosis and non-alcoholic steatohepatitis (NASH) evolution. This model was developped from data of 1801 severely obese, bariatric surgery candidates, with histological assessment, integrating duration of exposure to risk factors. It is then able to predict current disease severity in the absence of assessment, and future cirrhosis risk based on current stage. The model quantifies the impact of sex, body-mass index at 20, diabetes, age of overweight onset, on progression. For example, for 40-year-old severely obese patients seen by the general practitioners: (a) non-diabetic woman overweight at 20, and (b) diabetic man overweight at 10, without disease assessment, the model predicts their current risk to have NASH or F3-F4: for (a) 5.7% and 0.6%, for (b) 16.1% and 10.0% respectively. If those patients have been diagnosed F2 by the specialist, the model predicts the 5-year cirrhosis risk: 1.8% in the absence of NASH and 6.0% in its presence for (a), 10.3% and 26.7% respectively, for (b). This model provides a decision-making tool to predict the risk of liver disease that could help manage severely obese patients.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Submission date :
2021-07-06T12:48:57Z
2024-01-30T15:07:40Z
2024-01-30T15:07:40Z